Pervasis Therapeutics Inc. Harvard Case Solution & Analysis

In May 2005, Steve Bollinger was to become president and chief operating officer of Pervasis Therapeutics, a small cell therapy start in Cambridge, Massachusetts. If proven successful, the product Pervasis, Vascugel, can change the way the disease treatment and have serious consequences in a large and underserved population. However, Vascugel not yet gone into human clinical trials, and get it on the market will mean navigating the approval process FDA, as well as raising the capital needed to finance the operation. That was before Bollinger decide on a strategy for clinical trials Vascugel author. In addition, he will have to decide how much money the company has to increase, taking into account the interests of the company's founders and existing venture investors. Finally, while Bollinger, is expected to lead the company in the next two to three years, the board Pervasis "plans to launch a permanent CEO search in the future." Hide
by Robert F. Higgins, Virginia A. Fuller Source : Harvard Business School 29 pages. Publication Date: December 21, 2006. Prod. #: 807026-PDF-ENG

Pervasis Therapeutics Inc. Case Solution Other Similar Case Solutions like

Pervasis Therapeutics Inc.

Share This